ABSTRACT
Background & objectives: High mortality has been observed in the cancer population affected with COVID-19 during this pandemic. We undertook this study to determine the characteristics and outcomes of cancer patients with COVID-19 and assessed the factors predicting outcome. Methods: Patients of all age groups with a proven history of malignancy and a recent diagnosis of SARS-CoV-2 infection based on nasal/nasopharyngeal reverse transcriptase (RT)-PCR tests were included. Demographic, clinical and laboratory variables were compared between survivors and non-survivors groups, with respect to observed mortality. Results: Between May 11 and August 10, 2020, 134 patients were included from the three centres and observed mortality was 17.1 per cent. The median age was 53 yr (interquartile range 39-61 yr) and thirty four patients (25%) were asymptomatic. Solid tumours accounted for 69.1 per cent and breast cancer was the most common tumour type (20%). One hundred and five patients (70.5%) had received chemotherapy within the past four weeks and 25 patients (19.3%) had neutropenia at presentation. On multivariate analysis, age [odds ratio (OR) 7.99 (95% confidence interval [CI] 1.18-54.00); P=0.033], haemoglobin [OR 6.28 (95% CI 1.07-37.04); P=0.042] neutrophil–lymphocyte ratio [OR 12.02 (95% CI 2.08-69.51); P=0.005] and baseline serum albumin [OR 18.52 (95% CI 2.80-122.27); P=0.002], were associated with higher mortality. Recent chemotherapy, haematological tumours type and baseline neutropenia did not affect the outcome. Interpretation & conclusions: Higher mortality in moderate and severe infections was associated with baseline organ dysfunction and elderly age. Significant proportion of patients were asymptomatic and might remain undetected
ABSTRACT
Objective: To analyze the cytogenetic abnormalities of a largecohort of consecutive pediatric Acute Myeloid Leukemia (AML)patients, treated on a uniform protocol.Design: Review of case records.Setting: Pediatric Cancer Center of tertiary care hospital betweenJune 2003 and June 2016.Participants: 617 consecutive de novo pediatric AML patientswere screened and 472 patients were found eligible. Eligibilitycriteria included non M3 patients, successful cytogenetic profileand availability of complete recordsMain outcome measure: Cytogenetic profile.Results: Gum-hypertropy, chloromas and rate of completeremission were significantly different between EuropeanLeukemia Network classification (ELN) cytogenetic risk groups(P<0.01). t (8;21) (141, 29.8%), loss of Y chromosome (61,12.9%)and trisomy 8 (39, 8.3%) were the most common abnormalities.Among the chromosomal gains, trisomy 8 and trisomy 21 (bothP<0.01) were significantly different among the three ELN riskgroups. Among the chromosome losses, monosomy 5, 7 (bothP<0.01) and 9 (P=0.03), loss of X and loss of Y (both P<0.01)were statistically different amongst three cytogenetic risk groups.Event-free survival (P<0.01) and overall survival (P<0.01) werefound to be significantly different among the three risk groups.Conclusions: The higher frequency of t (8; 21) and its associationwith chloroma in Indian pediatric patients is different from otherstudies around the world.
ABSTRACT
Extrapancreatic solid pseudopapillary neoplasms (SPNs) are rare tumors, which bear morphological, immunohistochemical, and molecular features similar to those of pancreatic counterparts. SPN occurs primarily in adolescent girls and young women. It is considered to be a malignant neoplasm with low‑grade biology. Ovarian SPNs are uncommon, have benign morphology, usually limited to the ovary and local surgical excision is curative. We report an unusual case of SPN of right ovary with extraovarian spread and metastases to lymph nodes. To the best of our knowledge, this is the second documented case of extragonadal spread of ovarian SPN.